Opus Genetics (FRA:R3X1) Total Payout Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R3X1 Opus Genetics Inc FRA:R3X1
20 GF Score
Price €4.52
GF Value €0.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Opus Genetics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Opus Genetics's current Total Payout Ratio is .

Opus Genetics Total Payout Ratio Related Terms

Opus Genetics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Total Payout Ratio Chart

Opus Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Opus Genetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:R3X1 vs OBIO, CYDY, YDES: Total Payout Ratio Comparison

For the Biotechnology subindustry, Opus Genetics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Total Payout Ratio falls into.


FRA:R3X1
20GF Score
Opus Genetics Inc FRA:R3X1
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Opus Genetics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0.13468276597147 + 43.572533004258 + -0) / -43.941138469022
=0.99

Opus Genetics's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0.30753628770803 + 5.8730653086323 + -0) / -6.9647653168338
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Opus Genetics (FRA:R3X1) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of €4.52 is trading 1783.3% above its estimated GF Value™ of €0.24. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for FRA:R3X1:

  • Total Payout Ratio:
  • GF Value™: €0.24 vs. price of €4.52 (1783.3% above fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the FRA:R3X1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges IRD:USA
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score

Get the complete analysis for FRA:R3X1

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€0.24
GF Value